Risk of Severe Outcomes From COVID-19 in Comorbid Populations in the Omicron Era: A Meta-analysis

Publication date: Dec 02, 2024

Importance: This is the first meta-analysis to investigate risk of death and hospitalization in individuals with comorbidities, specifically during the Omicron era. Objective: To assess the risk of mortality and hospitalization from COVID-19 in individuals with comorbidities in comparison with individuals without comorbidities during the Omicron era. Data Sources: A systematic search of Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, and WHO COVID-19 Database was performed to identify studies published between 1 January 2022 and 13 March 2024. Study Selection: Inclusion criteria were observational studies including people (all ages) with at least 1 of the following comorbidities: cardiovascular/ cerebrovascular disease, chronic lung conditions, diabetes, and obesity. In total, 72 studies were included in the review, of which 68 were meta-analyzed. Data Extraction and Synthesis: Data were extracted by one reviewer and verified by a second. Studies were synthesized quantitively (meta-analysis) using random-effect models. PRISMA guidelines were followed. Main Outcomes and Measures: Evaluated outcomes were the risks of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes. Odds ratios, hazard ratios, and rate ratios were extracted; pooled relative risk (RR) and 95% confidence intervals (CI) were calculated. Results: Minimum numbers of participants per comorbidity across included studies ranged from 328 870 for thrombosis to 13 720 480 for hypertension. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, COPD, diabetes, respiratory diseases, heart disease, and heart failure versus those without (pooled RRs ranged from 1.27 [heart disease, hospitalization; 95% CI, 1.17-1.38, P < .001] to 1.78 [heart failure, death: 95% CI, 1.46-2.16, P < .001]). Individuals with diabetes and obesity had increased risk of ICU admission (RR: 1.20; 95% CI: 1.04-1.38, P = .0141 and RR: 1.32; 95% CI: 1.11-1.57, P = .00158, respectively). Conclusions: During the Omicron era, risk of death and hospitalization from COVID-19 is increased amongst individuals with comorbidities including cerebrovascular/cardiovascular conditions, chronic lung diseases, and diabetes, with the highest risk in those with heart failure. Individuals with diabetes and obesity are at increased risk of ICU admission.

PDF

Concepts Keywords
Cerebrovascular17 Al
Harvard Comorbidities
Korean Covid
Obesity36 Death
Diabetes
Heart
Hospitalization
Individuals
Medrxiv
Meta
Omicron
Outcomes
Preprint
Risk
Severe

Semantics

Type Source Name
disease MESH COVID-19
disease MESH death
disease MESH Data Sources
disease MESH cerebrovascular disease
disease MESH obesity
disease MESH comorbidity
disease MESH thrombosis
disease MESH hypertension
disease MESH COPD
disease MESH respiratory diseases
disease MESH heart disease
disease MESH heart failure
disease MESH lung diseases
disease MESH cardiovascular diseases
disease MESH infections
disease MESH complications
disease IDO infection
drug DRUGBANK Methionine
disease MESH asthma
pathway KEGG Asthma
disease MESH atrial fibrillation
disease MESH pneumonia
pathway REACTOME Apoptosis
disease MESH abnormalities
disease MESH stress cardiomyopathy
disease MESH acute respiratory distress syndrome
disease MESH interstitial lung disease
disease MESH bacterial infection
disease MESH lung injury
disease IDO susceptibility
disease MESH Cytokine storm
disease IDO blood
drug DRUGBANK Oxygen
disease IDO country
disease IDO geographical region
disease MESH morbidity
disease MESH Cardiovascular risk factors
disease MESH Acute ischemic stroke
disease MESH Fatal Outcome
drug DRUGBANK Ephedra
drug DRUGBANK Angiotensin II
drug DRUGBANK Aldosterone
disease MESH Stroke
disease IDO cell
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Overweight
disease MESH critically ill
disease MESH respiratory failure
disease MESH infectious diseases
disease MESH Allergy
drug DRUGBANK Imipramine
drug DRUGBANK Guanosine
drug DRUGBANK Isosorbide Mononitrate

Download Document

(Visited 1 times, 1 visits today)